Guggenheim Maintains Buy on NextGen Healthcare, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Jack Wallace maintains a Buy rating on NextGen Healthcare (NASDAQ:NXGN) but lowers the price target from $26 to $22.
May 23, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guggenheim analyst Jack Wallace maintains a Buy rating on NextGen Healthcare (NASDAQ:NXGN) but lowers the price target from $26 to $22.
The news directly mentions NextGen Healthcare (NASDAQ:NXGN) and the lowered price target by Guggenheim analyst Jack Wallace. While the Buy rating is maintained, the lowered price target may cause some uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100